Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by the BCR-ABL1
fusion gene generation as a consequence of the t (9; 22)(q34; q11) rearrangement. The …

Abstract Around 40–50% of patients with chronic myeloid leukemia (CML) who achieve a
stable complete molecular response (CMR; undetectable breakpoint cluster region-Abelson …

We used the genomic breakpoint between BCR and ABL1 genes for the DNA-based
monitoring of minimal residual disease (MRD) in 48 patients with childhood acute …

Molecular monitoring plays an essential role in the clinical management of chronic myeloid
leukemia (CML) patients, and now guides clinical decision making. Quantitative reverse …

Increasing numbers of patients with chronic myeloid leukaemia (CML) treated with tyrosine
kinase inhibitors achieve undetectable levels of BCR‐ABL mRNA using sensitive …

The BCR-ABL1 sequence has advantages over the BCR-ABL1 transcript as a molecular
marker in chronic myeloid leukemia and has been used in research studies. We developed …

The BCR-ABL oncogenic tyrosine kinase causes chronic myeloid leukemia and is the target
for imatinib therapy. During imatinib treatment, cells are selected in some patients with BCR …

A high percentage of patients with leukemia, lymphoma, and solid tumors achieve a
complete clinical remission after initial treatment, but the majority of these patients will finally …

Isolation and sequencing of the translocation breakpoint in chronic myeloid leukaemia‐
(CML) and acute promyelocytic leukaemia (APML) may help to elucidate the mechanism of …

In chronic myeloid leukemia, the identification of individual BCR-ABL1 fusions is required for
the development of personalized medicine approach for minimal residual disease …